ACUTA CAPITAL PARTNERS, LLC
An institutional investment manager in REDWOOD CITY, CA. Its Form 13F for the quarter ended Jun 30, 2026, filed Aug 14, 2026. SEC CIK 1582844.
- Reported value$143.5m
- Positions23
Holdings: 23 positions
The filing on sec.govAs filed, largest first. Reported value is what the manager stated for each position at the quarter end, in US dollars; it is filing data, not a price. Weight is the position's share of the total reported value. Changes compare with the 13F for the quarter ended 2026-03-31.
| Issuer | Class | CUSIP | Reported value$m | Weight | Shares | Put or call | Change on the quarter before |
|---|---|---|---|---|---|---|---|
| Praxis Precision Medicines IPRAX | COM NEW | 74006W207 | 27.7 | 19.3% | 82,796 | Reduced−2,105 | |
| Whitehawk Therapeutics IncWHWK | COM | 00032Q104 | 21.5 | 15.0% | 4,685,912 | Added+1,275,510 | |
| Tango Therapeutics IncTNGX | COM | 87583X109 | 12.2 | 8.5% | 390,949 | Reduced−50,882 | |
| Sutro Biopharma IncSTRO | COM | 869367201 | 9.0 | 6.3% | 270,251 | Added+826 | |
| Arrivent Biopharma IncAVBP | COM | 04272N102 | 7.6 | 5.3% | 218,694 | New+218,694 | |
| 4D Molecular Therapeutics IncFDMT | COM | 35104E100 | 6.8 | 4.7% | 507,801 | New+507,801 | |
| Bright Minds Biosciences IncDRUG | COM NEW | 10919W405 | 6.5 | 4.5% | 92,745 | Reduced−19,251 | |
| Ocular Therapeutix IncOCUL | COM | 67576A100 | 5.2 | 3.6% | 532,481 | Reduced−59,627 | |
| Erasca IncERAS | COM | 29479A108 | 4.9 | 3.4% | 265,199 | Reduced−89,376 | |
| Surrozen IncSRZN | COM NEW | 86889P208 | 4.5 | 3.1% | 173,395 | Added+548 | |
| Argen SE - AdrARGX | SPONSORED ADR | 04016X101 | 4.4 | 3.0% | 4,705 | Added+15 | |
| Moonlake ImmunotherapeuticsMLTX | CLASS ORD A | 61559X104 | 4.2 | 2.9% | 215,652 | Added+23,892 | |
| Design Therapeutics IncDSGN | COM | 25056L103 | 4.1 | 2.8% | 282,564 | Added+136,664 | |
| Minerva NeurosciencesNERV | COM NEW | 603380205 | 3.9 | 2.7% | 709,500 | Unchanged | |
| Taysha Gene Therapies IncTSHA | COM SHS | 877619106 | 3.8 | 2.7% | 561,808 | Added+122,344 | |
| Avalyn Pharma IncAVLN | COM SHS | 05348Y105 | 3.8 | 2.6% | 115,000 | New+115,000 | |
| Avalo Therapeutics IncAVTX | COM NEW | 05338F306 | 3.4 | 2.4% | 186,308 | Added+125,500 | |
| Amylyx Pharmaceuticals IncAMLX | COM | 03237H101 | 3.0 | 2.1% | 168,115 | Added+17,048 | |
| Artiva Biotherapeutics IncARTV | COM | 04317A107 | 2.5 | 1.8% | 260,416 | New+260,416 | |
| Compass Therapeutics IncCMPX | COM | 20454B104 | 1.3 | 0.9% | 595,213 | Reduced−253,863 | |
| United Therapeutics CorpUTHR | COM | 91307C102 | 1.2 | 0.8% | 2,224 | Unchanged | |
| Contineum Therapeutics Inc-ACTNM | CL A | 21217B100 | 1.0 | 0.7% | 63,095 | New+63,095 | |
| LB Pharmaceuticals IncLBRX | COM SHS | 50180M108 | 0.9 | 0.7% | 28,919 | Unchanged |
Sold out: 9 positions
Held at the end of the quarter before and not reported this quarter.
| Issuer | Class | CUSIP | Reported value$ | Weight | Shares | Put or call | Change on the quarter before |
|---|---|---|---|---|---|---|---|
| 4D Molecular Therapeutics Inc | COM | 35104E104 | 0.0 | 0.0% | 0 | Sold out−242,255 | |
| Entrada Therapeutics IncTRDA | COM | 29384C108 | 0.0 | 0.0% | 0 | Sold out−89,358 | |
| Ideaya Biosciences IncIDYA | CALL | 45166A102 | 0.0 | 0.0% | 0 | Call | Sold out−350 |
| Ideaya Biosciences IncIDYA | COM | 45166A102 | 0.0 | 0.0% | 0 | Sold out−48,234 | |
| Maze Therapeutics IncMAZE | COM | 578784100 | 0.0 | 0.0% | 0 | Sold out−19,335 | |
| Oculis Holding AG | ORDINARY SHARES | H5870P102 | 0.0 | 0.0% | 0 | Sold out−98,339 | |
| Revolution Medicines IncRVMD | COM | 76155X100 | 0.0 | 0.0% | 0 | Sold out−26,069 | |
| Terns Pharmaceuticals Inc | COM | 880881107 | 0.0 | 0.0% | 0 | Sold out−495,772 | |
| Unicycive Therapeutics IncUNCY | COM | 90466Y202 | 0.0 | 0.0% | 0 | Sold out−57,959 |
Source: SEC EDGAR, Form 13F-HR, accession 0001104659-26-096822 (on sec.gov). Last ingested by Listed: Oct 22, 2026, 05:26 ET. Listed shows no prices and gives no investment advice.